New opportunities in sight as first sales approach

Immunovia is on track to start commercialising its PanCan-d test for the early detection of pancreatic cancer in high-risk patients in 2018. To this end, it has established its US headquarters in Boston, which includes a laboratory regulated via the Clinical Laboratory Improvement Amendments (CLIA) programme. It has also identified a new important opportunity for the PanCan-d test in the early pancreatic cancer symptoms group, has announced further positive data on the differentiation of autoimmune diseases, and continues the preparations for a retrospective study and a biomarkers study in the diabetic population. Our valuation is SEK157/sh.